Canopy Growth Corporation CGC WEED recently unveiled financial results for the third quarter ending on Dec. 31, 2022.
Among the announcements the company made included a headcount reduction of approximately 60%.
Here's a breakdown of the report:
- Net revenue of CA$101 million ($75.4 million), a 28% decrease compared to Q3 FY2022.
- Gross margin was (2%) as compared to 7% in Q3 FY2022.
- Net loss CA$267 million, which is a CA$151 million increase in the net loss versus Q3 FY2022.
- Adjusted EBITDA loss was CA$88 million, a CA$21 million increase in adjusted EBITDA loss versus Q3 FY2022.
- The company is transitioning to an asset-light model in Canada by exiting cannabis flower cultivation in the company's Smiths Falls, Ontario facility
- It will also cease sourcing cannabis flower from the Mirabel, Quebec facility
- Canopy will be moving to a third-party sourcing model for cannabis beverages, edibles, vapes, and extracts.
The Analyst
Following the report, Cantor Fitzgerald’s Pablo Zuanic maintained a ‘Neutral’ rating on Canopy Growth’s stock, reducing the price target from $3.3 to $3.2.
The Thesis
The analyst lowered the price target as recreational cannabis market in Canada poses significant structural challenges, and several companies have not been able to find a way to be profitable there. While some companies have diversified into other industries or downsized their recreational exposure, Canopy Growth is switching to asset-light model in Canada.
The analyst noted that the stock has recovered almost half of the 17% drop seen on 2/9 (S&P500 flat), down only 10% since then, and that of all the Canadian Cannabis companies, the stock remains the most directly exposed to U.S. legalization.
Zuanic also noted that his takeaway from last week’s call was positive: the probability it will remain NASDAQ-listed has increased, and the company may be able to find other ways to show the performance of the U.S. assets without consolidating them outright.
The Price Action
Canopy Growth shares were trading 1.43% lower at $2.405 per share at the time of writing Friday morning.
Benzinga's Cannabis Capital Conference Is Back
The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.